New long-term data suggests Abatacept treatment

June 22, 2006

New data from the long-term extension of the AIM (Abatacept in Inadequate responders to Methotrexte) trial, announced today at the Annual European Congress of Rheumatology, suggests the selective T-cell co-stimulation modulator abatacept sustains inhibition of radiographic progression over 2 years in rheumatoid arthritis patients with an inadequate response to methotrexate.

Abatacept (a disease modifying agent which blocks the signal of blood that is necessary for T-cells to damage joints in arthritis) has previously demonstrated significant reductions in radiographic progression (a measure showing the extent of actual damage to joints) in rheumatoid arthritis patients with an inadequate response to methotrexate (an antimetabolite drug which inhibits the synthesis of DNA, RNA and protein) during the double-blind phase of the AIM trial1. As such the extension arm aimed to investigate long term impact.

433 vs. 219 patients were randomized and treated with abatacept vs. placebo, with 385 (88.9%) vs. 162 (74.0%) completing the double blind phase. 539 patients were treated with Abatacept in the long-term extension arm of the study.

Data shows that 2 years of abatacept treatment slowed progression of structural damage in RA patients with an inadequate response to methotrexate, with the effect seen at year 2 significantly better than those in year 1.

In patients treated with abatacept for 2 years, minimal radiographic progression was observed during the second year of treatment. Using a linear mixed model analysis to compare the slope of radiographic progression over the 2-year period, abatacept was found to be significantly better than 1 year of placebo followed by 1 year of abatacept. Radiographic progression in the abatacept group slowed during year 2 vs. year 1.

"The long term extension of the AIM study shows that 2 yrs of abatacept treatment slowed progression of structural damage in rheumatoid arthritis patients, potentially providing a valuable treatment option for those patients with an inadequate response to methotrexate" explained Harry K. Genant, study lead and Professor Emeritus, University of California San Francisco and Chairman Emeritus Synarc, San Francisco, United States. "It is especially interesting to note that the effect seen at year two was significantly better than that seen at year one, suggesting progressive improvement and sustained reduction of damage which could equate to increased patient quality of life measures such as mobility and independence" he continued.
-end-
References

1. Genant et al. Ann Rheum Dis 2005;64(Suppl III):56

For further information on this study, or to request an interview with the study lead, please do not hesitate to contact the EULAR congress press office on:

Email: eularpressoffice@uk.cohnwolfe.com

Jim Baxter - Onsite tel: +44 (0) 7900 605652
Jo Spadaccino - Onsite tel: +44 (0) 7773 271930
Mia Gannedahl - Office tel: +44 (0) 20 7331 2325

Abstract number: OP0015

About EULAR

European League Against Rheumatism

Related Arthritis Articles from Brightsurf:

Physical activity and sleep in adults with arthritis
A new study published in Arthritis Care & Research has examined patterns of 24-hour physical activity and sleep among patients with rheumatoid arthritis, lupus, and knee osteoarthritis.

Is rheumatoid arthritis two different diseases?
While disease activity improves over time for most rheumatoid arthritis (RA) patients, long-term outcomes only improve in RA patients with autoantibodies, according to a new study published this week in PLOS Medicine by Xanthe Matthijssen of Leiden University Medical Center, Netherlands, and colleagues.

Does the Mediterranean diet protect against rheumatoid arthritis?
Previous research has demonstrated a variety of health benefits associated with the Mediterranean diet, which is rich in olive oil, cereals, fruit and vegetables, fish, and a moderate amount of dairy, meat, and wine.

Reducing corticosteroid use in rheumatoid arthritis
Is the long-term use of glucocorticoids essential in people with chronic inflammatory diseases such as rheumatoid arthritis, or can early discontinuation prevent characteristic side effects?

Psoriasis onset determines if psoriatic arthritis patients develop arthritis or psoriasis first
In a new study presented at the 2019 ACR/ARP Annual Meeting, researchers found the age of psoriasis onset determines whether arthritis or psoriasis starts first in people with psoriatic arthritis.

The ACR and the Arthritis Foundation present new guidelines offering therapeutic approaches and treatment options for juvenile idiopathic arthritis
Today, the American College of Rheumatology (ACR), in partnership with the Arthritis Foundation (AF), released two guidelines on juvenile idiopathic arthritis (JIA).

Does alcohol consumption have an effect on arthritis?
Several previous studies have demonstrated that moderate alcohol consumption is linked with less severe disease and better quality of life in patients with rheumatoid arthritis, but a new Arthritis Care & Research study suggests that this might not be because drinking alcohol is beneficial.

Prospect of a new treatment for rheumatoid arthritis
An international research group led by Charité -- Universitätsmedizin Berlin has completed testing a new drug to treat rheumatoid arthritis.

Can rare lymphocytes combat rheumatoid arthritis?
Immunologists at Friedrich-Alexander-Universität Erlangen-Nürnberg have demonstrated that ILC2, a group of rare lymphoid cells, play a key role in the development of inflammatory arthritis.

Which pain medication is safest for arthritis patients?
In a recent Alimentary Pharmacology & Therapeutics study, arthritis patients taking nonsteroidal anti-inflammatory drugs (NSAIDs) for pain plus a stomach acid-reducing medicine called esomeprazole had infrequent gastrointestinal side effects.

Read More: Arthritis News and Arthritis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.